Outcome MeasureSubstance Use

COWS

Clinical Opiate Withdrawal Scale

2 Papers in Blossom

Outcome Data Across Studies

Reported results for COWS across 2 studies with quantitative data.

Outcome data across 4 study arm–timepoint observations
SD
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Secondary
Ibogaine single dose(experimental)0140.0——
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Secondary
Ibogaine single dose(experimental)1140.0——
Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
2023Secondary
Participant 1 dose 1(experimental)013.0——
Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
2023Secondary
Participant 1 dose 1(experimental)0.042114.0——

Papers Using COWS

Paywallindividual

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings

This safety-feasibility trial (n=2) explored the interaction between psilocybin and buprenorphine in adults with opioid use disorder (OUD). The study found that coadministration of psilocybin and buprenorphine was safely tolerated, with no serious adverse events or significant changes in opioid craving or withdrawal measures. Feasibility challenges led to modifications in the study population and eligibility criteria, emphasizing the need for improved accessibility and overall generalizability.

Published
Journal
Psychedelic Medicine
Authors
Nicholas, C. R., Horton, D. M., Malicki, J., Baltes, A., Hutson, P. R., Brown, R. T.
Open Accessindividual

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study

This open‑label study (n=14) of opioid‑dependent patients given a single 700 mg per 70kg dose of ibogaine‑HCl, treatment produced clinically relevant but reversible cardiac and cerebellar toxicity. The mean maximal QTc(F) prolongation was 95 ms, with 50% of participants exceeding 500 ms, accompanied by bradycardia and severe transient ataxia. Psychomimetic and withdrawal effects were generally manageable, and no torsades de pointes were observed.

Published
Journal
Addiction
Authors
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Kramers, C., Verkes, R. J.

Quick Facts

Full Name
Clinical Opiate Withdrawal Scale
Domain
Substance Use
Papers Indexed
2
Score Range
0–48
Interpretation
Lower = better
All Measures